Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 July 2022 | Story Lacea Loader

The Council of the University of the Free State (UFS) approved the lifting of the institution’s COVID-19 Regulations and Required Vaccination Policy with immediate effect.

“Since the declaration by the Government on 22 June 2022 that the COVID-19 regulations will be repealed, the UFS has conducted a risk assessment to determine the risk of exposure to staff and students. From the assessment, it was clear that the university’s COVID-19 infections are currently a low risk,” said Prof Francis Petersen, Rector and Vice-Chancellor of the UFS.

Factors that contributed to this low risk include the following:

  • No COVID-19 positive cases among UFS staff and students have been reported in the past month.
  • The high number of vaccinations among UFS stakeholders. In addition, the current national immunity level of the total South African population is high.
  • Certain faculties and postgraduate students are currently proceeding with hybrid/online learning, which minimises the risk of possible COVID-19 infections on the university’s three campuses.
  • In its correspondence of 23 June 2022, the UFS urged all staff and students to continue wearing masks should they have comorbidities and/or symptoms of illness, thus safeguarding other stakeholders.

“We believe that COVID-19 no longer poses an immediate threat to the safety of our staff and students, and that the pandemic is at a stage where they should take responsibility for their own safety. This can be mainly ascribed to the success of the implementation of the policy. Staff and students who still wish to wear masks are urged to do so at their own discretion. Those who have not yet been vaccinated against the virus and have no

known condition preventing them from doing so, are advised to get vaccinated for their own safety and protection,” said Prof Petersen.

The UFS COVID-19 Regulations and Required Vaccination Policy was approved by the University Council on 26 November 2021 and implemented on 6 December 2021. The university commenced restricting unvaccinated individuals from accessing its campuses as of 14 February 2022.

“If the national regulatory environment with respect to COVID-19 is changing to such an extent that the policy needs to be re-implemented, the university’s executive management will act accordingly, and hence the COVID-19 Regulations and Required Vaccination Policy remains a policy of the university as approved by the UFS Council on 26 November 2021.” said Prof Petersen.

 

Uplifting of the COVID-19 vaccination policy - mitigation strategies of the University of the Free State.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept